LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $88.31, for a total value of $88,310.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Daniel Jeffrey Moore also recently made the following trade(s):
- On Thursday, February 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $83.32, for a total value of $83,320.00.
- On Tuesday, January 16th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $82.15, for a total value of $82,150.00.
Shares of LIVN opened at $86.05 on Wednesday. LivaNova PLC has a 12-month low of $49.68 and a 12-month high of $92.31. The company has a current ratio of 2.14, a quick ratio of 1.79 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $4,131.74, a P/E ratio of 24.24, a PEG ratio of 2.67 and a beta of 0.75.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, February 28th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.10. LivaNova had a positive return on equity of 9.37% and a negative net margin of 2.10%. The company had revenue of $278.40 million for the quarter, compared to analysts’ expectations of $278.48 million. During the same period last year, the business earned $0.83 EPS. LivaNova’s quarterly revenue was up 11.5% compared to the same quarter last year. sell-side analysts forecast that LivaNova PLC will post 3.2 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Cerebellum GP LLC bought a new position in LivaNova during the 4th quarter valued at $128,000. QS Investors LLC lifted its stake in LivaNova by 27,255.6% during the 4th quarter. QS Investors LLC now owns 2,462 shares of the company’s stock valued at $197,000 after acquiring an additional 2,453 shares in the last quarter. Pillar Pacific Capital Management LLC bought a new position in LivaNova during the 4th quarter valued at $208,000. Affinity Investment Advisors LLC bought a new position in LivaNova during the 4th quarter valued at $211,000. Finally, Rehmann Capital Advisory Group bought a new position in LivaNova during the 4th quarter valued at $216,000. Institutional investors own 85.51% of the company’s stock.
LIVN has been the topic of a number of research analyst reports. Zacks Investment Research cut LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. BidaskClub cut LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and set a $104.00 price target (up from $97.00) on shares of LivaNova in a report on Wednesday, February 28th. Finally, Canaccord Genuity increased their price target on LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $81.43.
ILLEGAL ACTIVITY NOTICE: “Daniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (NASDAQ:LIVN) Stock” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/11/daniel-jeffrey-moore-sells-1000-shares-of-livanova-plc-livn-stock.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.